

Half Year Report

August 16, 2010



Letter to Our Stockholders

Dear Stockholders,

Substantial sales growth and a greatly improved result: NEXUS completed the first half year 2010 very successfully. We are starting into the second quarter 2010 with this good news. As a result, we are continuing the positive trend of the past years and furthering our development with a great number of new customers, who decided in favor of NEXUS in the first half year.

2 We are convinced that this on-going positive development is mainly due to our long-term strategy, which puts a convincing product program and healthy, profitable growth in the forefront. Our market and our customers appreciate this mixture of purposeful innovation and continuity and make it possible for us to win further market shares nationally and internationally.

For example, we acquired larger orders for introducing our Hospital Information System (NEXUS / HIS) from the Protestant Clinical Center in Stuttgart, Vinzenz von Paul Hospital in Rottweil, the psychiatry center in Rickling and five additional hospitals in the Swiss Canton of Fribourg and consequently proved how positively our new products are being accepted on the market. Our software products support numerous hospital processes in the projects and are relieving hospital staff of routine and documentation work as a result.

The same applies to our solutions specific for wards and departments (NEXUS / DIS), i.e., software support of special diagnostic process (e.g., radiology) in hospitals. We were able to win important orders in the areas of pathology and radiology in the first half year and expand our market position in these segments.

We were also able to acquire several hospital associations as new customers for NEXUS / CURATOR in the product area of quality management. This is a product that especially simplifies knowledge management in hospitals and consequently supports the trend to quality control and uniform treatment guidelines. NEXUS is market leader among software companies in this very important area for hospitals. Two basic tendencies have become clear with respect to

Highlights 1st Half Year - 2010 Development of Business

- + Strongly increase in sales; especially in the Healthcare Software segment
- + New orders of NEXUS / KIS
- + Increase of international sales

project implementation over the past months. On one hand, we are succeeding in reducing the introduction times of our systems further and providing customers with the expected advantages of the software more quickly. This has been demonstrated in the new projects in the Kiel Metropolitan Hospitals and in Mosbach as well as in the operation startup of two hospitals on the Turks & Caicos Islands, for example. We started operation of complete projects there within respectively very short times. On the other hand, we see that our regular customers are investing decisively in enhancements. The topics of medication, pharmacy, emergency care as well as management and knowledge information systems are currently being implemented as additional projects and supporting our customers in digitalizing their hospital processes more comprehensively.

Following the very successful introduction of NEXUS / HIS last year, our development is also focusing on these topics. The core process of medication is the focal point here. It is a matter of enhancing the existing solution even more and fulfilling the demands of our customers for depiction of additional medication processes and ergonomic improvements. However, we are also very active in elaborating new solutions in the topics of the emergency care department and management information systems (MIS). We especially made investments in MIS over the past weeks, which will advance our technology even more.

The development of our international patient management is certainly one of our special features. We are working on depicting the internationally very different patient management invoicing processes with an easy-to-parameterize solution.

We are already implementing customer projects in the first two countries. There is great potential for internationalization here and for differentiating us very strongly from our competitors. We are convinced that we are supporting development of our company decisively with this long-term and innovative development project. We can see in the first half-year figures that this strategy is bearing fruit.

We succeeded in continuing the unbroken positive development of the past years and in increasing both our sales and result strongly. Sales increased in the first half year by approx. 10.1% from EUR 18.8 million to EUR 20.7 million.

The operating result improved even more. The result before taxes increased by approx. 61% to EUR 1.58 million following EUR 0.98 million in the first half year of the previous year. The result was approx. EUR 1.53 million after taxes (previous year: EUR 0.85 million), and consequently we achieved an increase of 80%.

The operative cash flow is also to be emphasized here. We achieved a five percent increase from EUR 5.4 million during this period following EUR 3.6 million in the previous year.

There were considerable changes in balance sheet positions compared to 31 December 2009. We adapted risk precautions with increased reserves and reduced our accounts payable. At the same time, our liquid assets (EUR 13.9 million) increased substantially thanks to the good result. Accounts payable decreased again compared to the first quarter, but are slightly higher at 12.7 million than the value at the end of 2009 (EUR 12.5 million).

We are confirming the already good first quarter and the long-term trend of our company with this strong half-year result. We are going to have to prove in the second half year that we can also achieve these increase rates in the future too. The challenges are not minor that we are facing in current projects and in canvassing new markets. However, if we consider our good technological position and the continual increasing of our market shares and thus sales, we are confident that we can master these challenges.

It is also good news that we have been able to depict our positive development on the capital market and stimulate a lot of interest among investors, so that sales of our stocks have increased considerably on the securities market. Even though we are not yet satisfied with the price development of our stocks, we can see that the discrepancy between our company development and stock prices has become smaller. We hope that this development continues.

With respect to our business, we are determined to support the positive development on the securities market with continually increasing business figures. It is also our goal to be among the top companies in our market segment with respect to sales and result.

Sincerely,




Dr. Ingo Behrendt
CEO - NEXUS AG

Interim Annual Report - Sales: Increase in the First Half Year

NEXUS Group sales increased from KEUR 18,829 to KEUR 20,731 (+10.1%) in the first six months of the year 2010.


The **Healthcare Software** segment is responsible for the good development of sales; its sales increased by 11.1% compared to the same period of the previous year **from KEUR 16,667 to KEUR 18,510**. Sales in the area of **Healthcare Service** increased by 2.7% **from KEUR 2,162 to KEUR 2,221**.

4

In a **quarterly comparison** to the previous year, **sales of the Group increased by 11.7%** to KEUR 10,403 (Q2-2009: KEUR 9,316).

The **sales growth** is especially due to the greater number of sales in **international business** and increased demand **in Germany**.

Our increased sales in the product areas NEXUS / HIS, NEXUS / QM and NEXUS / PATHOLOGY are certainly to be emphasized here. We are currently experiencing a high demand in these product areas.



Highlights 1st HY - 2010 Sales and Result

- + 10.1% sales increase in first HY-2010 from EUR 18.8 million (in 2009) to EUR 20.7 million
- + 60.6% increase in result before taxes from EUR 0.98 million to EUR 1.58 million
- + Strongly positive operative cash flow (+50.0%) to EUR 5.4 million
- + Increase of liquid assets by EUR 2.3 million to EUR 13.9 million

Sales by regions	01/01/ -	01/01/ -	Δ in %	04/01/ -	04/01/ -	Δ in %
	06/30/09	06/30/10		06/30/09	06/30/10	
	KEUR	KEUR		KEUR	KEUR	
Germany	12,099	12,737	5,3	6,184	6,340	2,5
Switzerland	4,230	5,654	33,7	2,015	2,884	43,1
Austria	429	591	37,8	172	146	-15,1
Italy	75	12	-84	47	12	-74,5
Rest of Europe / USA	1,136	1,737	52,9	868	1,021	17,6
Arabien region	860			30		
Total	18,829	20,731	10,1	9,316	10,403	11,7

Sales by divisions	01/01/ -	01/01/ -	Δ in %	04/01/ -	04/01/ -	Δ in %
	06/30/09	06/30/10		06/30/09	06/30/10	
	KEUR	KEUR		KEUR	KEUR	
Healthcare Software	16,667	18,510	11,1	8,278	9,408	13,7
Healthcare Service	2,162	2,221	2,7	1,038	995	-4,1
Total	18,829	20,731	10,1	9,316	10,403	11,7

Interim Report - Result: Continued essential Increase


We were able to continue the positive development of results of the last years during the reporting period. The result before taxes improved by 60.6% to KEUR 1,576 (1st half-year 2009: KEUR 981).

We were also able to improve the **EBITDA** by approx. **21% from KEUR 3,359 to KEUR 4,073**. It should be noted here that one-time effects and **expenses for company integration** are also represented in their complete amount in the operating result this year. **Development costs** were capitalized unchanged and amounted to **KEUR 2,234** in the first half year. At the same time, intangible assets were written off in the amount of KEUR 2,733.



The **Healthcare Software** segment with a **result before taxes of KEUR 1,391 following KEUR 602** was much higher than in the previous year (+131%), while the **Healthcare Service** segment recorded a **decrease in its result to KEUR 185** (previous year: KEUR 380). The reasons for this decline are especially due to accounting procedures.

The operative cash flow of KEUR 5,412 is approx. 50.0% higher than the previous year's level at (1st half year 2009: KEUR 3,608). The liquid assets of NEXUS AG increased further and were EUR 13.86 million as of 30 June 2010 (12/31/2009: € 11.52 million).

The number of employees increased by 6 compared to the previous year to the current number of 362. The increase in was mainly in the Healthcare Software area.



5



Innovation: NEXUS / INOVISION – Fast Picture Management with Comprehensive Findings

The NEXUS radiology solution stands for perfect interaction of structured patient management, comprehensive documentation of findings and secure archiving. Standardized interfaces to HIS and imaging equipment ensure manufacture-independent exchange of data. These factors guarantee optimization of your radiological processes. With the new version 5.2.0, NEXUS / INOVISION is again taking a leading market position with respect to functions. Two new projects were won directly at the market launch.


6

NEXUS / INOVISION also supports users from existing systems and consequently provides integrated picture access. Optimum workflow from the availability of current and previous pictures and all the way to their availability to ward doctors is thus ensured with NEXUS / INOVISION. High-performance X-ray demonstrations for radiologists to conduct efficient discussions with and about patients are supported optimally and very flexibly by specific demonstration lists. These are arguments, which were also convincing for two hospitals, which decided in favor of the new NEXUS / INOVISION almost simultaneously with their introduction to the market. The two customers, which are highly regarded in the industry, cannot be named due to blocking periods. The extent to which their decisions will support our success in the hotly contested radiology market will be seen in the near future.

Easy-to-operate tools make complex diagnosis procedures possible using X-rays. The multifaceted options for interacting with the picture data and for specific presentation depending on the user (hanging protocols) provide means for individual optimization of efficient establishment of findings. The functions for patient CDs, export and printing enable forwarding pictures precisely depending on requirements. Pictures can be sent internally or externally, additionally guaranteeing the shortest paths to the right decisions. Web-based picture distribution and consideration is possible throughout hospitals and between different hospitals, and encoding provides a high degree of security at the same time. Easy access is made possible for all involved thanks to standard browsers such as Microsoft Explorer and Mozilla Firefox. Examination-related retrieval of pictures and findings is easy and can be integrated into any ward applications.


New functions, for example, the new 3D navigation

The new 3D visualization solution for picture diagnosing as well as processing digital X-rays and cross-section images help hospital staff to improve diagnosis possibilities and make them considerably faster. The 3D navigation enables display of the sublayers of associated series of a study using lines, which can be completely added, switched off and suppressed selectively in the viewer. In addition, a specific point can be selected in a series with the 3D navigation, to which the other associated series are aligned automatically. This makes simpler orientation possible in examinations of the spinal column, for example.



Although the market launch of the new version NEXUS / INOVISION 5.2.0 started very successful with two new projects.

NEXUS in the Environment of Financial and Health Markets



Following the opening price of € 3.30 at the beginning of the year and an increase by the middle of January up to € 3.75, NEXUS shares declined in value from the middle of January until the end of March. Prices ranged from € 3.40 to € 3.70 during this phase. The price started to drop strongly at the beginning of April until it even fell below € 3.00 in the middle of May. Prices of NEXUS shares again rose to the spring level of € 3.50 from the middle to the end of May. There was another decline in this range until the beginning of July. The share price rose again in July to more than € 4.00 for the first time in three years. The share price is currently approximately at this value. Compared to the course of the TecDax index from the beginning of the year until now, NEXUS shares have performed very positively with a further development of approx. +20% compared to -10% of the TecDax index.

Finance- and Event schedule 2010 (status quo: August '10)

FINANCE SCHEDULE

Quarterly Report - third quarter	November 8
German equity forum, Frankfurt (D)	November 22 - 24

EVENT AND TRADE FAIR SCHEDULE

eHealthcare congress, Nottwil (CH)	September 22 - 23
IFAS, Zurich	October 26 - 29
KTQ-Forum, Berlin	November 26 - 27
MEDICA & BeraterDialog, Düsseldorf	November 17 - 20
DGPPN, Berlin	November 24 - 27

Decisions for NEXUS-solutions 2010

- + Kliniken an der Paar, Aichach
- + St. Josef-Hospital, Bochum
- + St. Josefs-Hospital, Dortmund
- + Städtisches Krankenhaus, Eisenhüttenstadt
- + Kreiskrankenhaus Eschwege
- + Katholische Kliniken, Essen
- + Gemeinschaftspraxis für Pathologie, Fulda
- + Gelderland-Klinik, Geldern
- + Fachkrankenhaus Christophsbad, Göppingen
- + Kreiskrankenhaus Grevenbroich
- + Klinikum, Gütersloh
- + Gemeinschaftspraxis für Rad. und Nuklearmed., Cologne
- + Radiologie Köln-Kalk, Cologne
- + Gesellschaft für Parität. Sozialarbeit, Mainz
- + Krankenhaus Ludmillenstift, Meppen
- + Gemeinschaftspraxis für Pathologie, Mühlhausen
- + Rotkreuzklinikum, Munich
- + Ortenau Klinikum, Offenburg
- + St. Josefsklinik, Offenburg
- + Kreisklinik am Steinenberg, Reutlingen
- + Psychiatrisches Zentrum, Rickling
- + Klinikum Obergöltzsch, Rodewisch
- + Vinzenz von Paul Hospital, Rottweil
- + Kardinal Schwarzenberg'sches Krankenhaus, Schwarzach
- + Pathologische Praxis, Spaichingen
- + Diakonie-Klinikum, Stuttgart
- + Gemeinschaftspraxis für Pathologie, Stuttgart
- + Vinzenz von Paul Kliniken - Marienhospital, Stuttgart
- + St. Anna Krankenhaus, Sulzbach-Rosenberg
- + Gesundheitszentrum, Treuchtlingen
- + Radiologische Praxis, Trier
- + Kliniken des Landkreises Weißenburg-Gunzenhausen
- + Klinikum Wels-Grieskirchen, Wels
- + Lahn-Dill-Kliniken, Wetzlar
- + Missionsärztliche Klinik, Würzburg
- + AZ Ziekenhuis St.-Dimpna, Geel (BE)
- + Centre Hospitalier de Mouscron, Mouscron (BE)
- + Hôpital Cantonal, Fribourg (CH)
- + Kantonsspital, Liestal (CH)
- + Hôpital Psychiatrique Cantonal de Marsens, Marsens (CH)
- + Dronning Ingrid's Hospital, Nuuk (DK)
- + Hospital Hispania, Madrid (ES)
- + Hospital Clinico Universitario de Valladolid, Valladolid (ES)
- + Sykehuset Innlandet, Gjøvik (NO)
- + Rikshospitalet, Oslo (NO)
- + St. Olavs Hospital, Trondheim (NO)

Intermediate Annual Report

Group Informationen and Outlook

Directors Holdings

The Director's Holdings of the supervisory board and the executive board were as follows on June 30, 2010 in comparison to the previous year: see to the right

Chances and Risks

8 We were able to complete the first half year very successfully. Sales increases of 10.1% and an increase of the result before taxes of 60.6% are very pleasing results. The same applies to the cash flow, which is very noteworthy for the first half year at EUR 5.4 million. Although we already had outstanding increase rates in the previous years, we have still been able to improve our figures continually. But the challenge remains to keep these increase rates in the current year. We are going into the second half year confident that the reason for our good development is our long-term orientation and that is not due to short-term effects. Consequently, our confidence is based on our product program and the market feedback, which we get from our customers. Especially the order successes in Germany of the past months demonstrate that we are seen very positively on the market at this time. We see potential here that goes far beyond that which we have already achieved. However, we first have to push forward our ambitious development projects and challenging customer projects. They are critical for the success of our future development, and it will be a matter of working on them with all our might. It is obvious that the NEXUS staff has the will to success and commitment to invest the energy required to make our goals into a reality.

Financial situation

There are no significant changes in the financial situation of the group compared to 12/31/2009.

DIRECTORS HOLDINGS	Number of stock owned	Numbers of options
--------------------	-----------------------	--------------------

SUPERVISORY BOARD

Dr. jur. Hans-Joachim König	99,239	0
	Prev. year (81,099)	Previous year (0)
Prof. Dr. Alexander Pocsay	121,500	0
	Prev. year (0)	Previous year (0)
Erwin Hauser	15,000	0
	Prev. year (15,000)	Previous year (0)
Prof. Dr. Ulrich Krystek	0	0
	Prev. year (0)	Previous year (0)
Dipl.-Betriebswirt (FH) Wolfgang Dörflinger	0	0
	Prev. year (0)	Previous year (0)
Matthias Gaebler	0	0
	Prev. year (0)	Previous year (0)

EXECUTIVE BOARD

Dr. Ingo Behrendt (MBA)	112,000	57,000
	Prev. year (112,000)	Prev. year (149,154)
Ralf Heilig (MBA)	129,350	6,000
	Prev. year (129,350)	Prev. year (30,000)
Edgar Kuner (Dipl. Ingenieur)	264,051	6,000
	Prev. year (264,051)	Prev. year (25,000)

Facts and Figures

Group P+L Account as of 06/30/2010 and 06/30/2009 (IFRS)

CONSOLIDATED PROFIT AND LOSS ACCOUNT	04/01/ - 06/30/10	04/01/ - 06/30/09	01/01/ - 06/30/10	01/01/ - 06/30/09
	KEUR	KEUR	KEUR	KEUR
Revenue	10,430	9,316	20,731	18,829
Increase / decrease in finished goods and work in progress	-67	-6	-67	-31
Other capitalized company work	1,221	941	2,234	1,953
Other operating income	1,424	1,059	1,736	1,440
Cost of materials	3,198	2,110	4,931	4,239
Personnel expenses	5,832	5,364	11,442	10,585
Depreciation and amortization of fixed intangible and tangible assets	1,399	1,284	2,733	2,563
Other operating expenses	1,940	2,173	4,188	4,008
OPERATING INCOME	612	379	1,340	796
Expenses from associated companies	0	0	0	0
Interest and similar income	160	57	263	200
Interest payable and other similar charges	23	4	27	14
PROFIT BEFORE TAX	749	432	1,576	982
Income taxes	-122	43	38	133
PERIOD RESULT	871	389	1,538	849
Actuarial profits and losses (after taxes on profit)	-9	4	-19	8
Differences from the conversion of foreign currency	137	-47	143	-81
Market value changes from assets available for sale (after taxes on profit)	-28	204	52	148
OTHER OVERALL RESULT	100	161	176	75
OVERALL RESULT OF THE PERIOD	971	550	1,714	924
Of the period result, attributed to:				
- Stockholders of NEXUS AG	871	363	1,498	803
- Minority interests	0	26	40	46
Of the overall result, attributed to:				
- Stockholders of NEXUS AG	971	524	1,674	878
- Minority interests	0	26	40	46
PERIOD RESULT PER SHARE IN EUR				
Weighted Average of Issued Shares in Circulation (in Thousands)	13,797	13,797	13,797	13,797
- simple	0.07	0.03	0.11	0.06
- diluted	0.07	0.03	0.11	0.06

Facts and Figures

Balance sheet as of 03/31/2010 and 12/31/2009 (IFRS)

10

ASSETS	06/30/2010	12/31/2009
	KEUR	KEUR
LONG-TERM CAPITAL		
Goodwill	11,642	11,642
Other intangible assets	16,819	16,629
Fixed Assets	1,035	1,079
Shares in affiliated companies	98	98
Credited deferred taxes	2,609	2,486
Other financial assets	79	98
TOTAL LONG-TERM CAPITAL	32,282	32,032
SHORT-TERM CAPITAL		
Inventories	187	169
Trade receivables and other receivables	12,727	12,588
Receivables from tax on profits	181	350
Other non-financial assets	1,386	552
Other financial assets	1,526	1,577
Securities	2,055	1,981
Cash and balance in bank	11,802	9,538
TOTAL SHORT-TERM CAPITAL	29,864	26,755
TOTAL ASSETS	62,146	58,787

Facts and Figures

Balance sheet as of 06/30/2010 and 12/31/2009 (IFRS)

TOTAL LIABILITIES	06/30/2010	12/31/2009
	KEUR	KEUR
EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY		
Subscribed capital	13,805	13,805
Capital reserve	39,523	39,523
Net loss for the year	-4,397	-5,895
Other cumulated Group result	-433	-608
Own shares	-26	-26
EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY	48,472	46,799
Minority interest	283	243
TOTAL EQUITY	48,755	47,042
LONG-TERM LIABILITIES		
Pension provisions	674	610
Other provisions	1,223	1,018
TOTAL LONG-TERM LIABILITIES	1,897	1,628
SHORT-TERM LIABILITIES		
Deferments	1,893	776
Financial liabilities	4	290
Trade accounts payable	2,194	3,515
Liabilities from tax on profit	391	80
Deferred revenue liability	3,063	345
Other non-financial debts	742	2,257
Other financial debts	3,207	2,854
TOTAL SHORT-TERM LIABILITIES	11,494	10,117
TOTAL EQUITY AND LIABILITIES	62,146	58,787

CASH FLOW	2010	2009
	KEUR	KEUR
1. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	1,576	981
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	2,733	2,563
Other expenses / income with no impact on cash	-106	-314
Depreciation of financial assets	-18	35
Profit / loss from disposal of long term capital	0	0
Profit / loss from disposal of securities	0	136
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	-1,057	-2,219
Changes in provision	823	651
Increase / decrease in trade accounts payable and other liabilities that cannot be allocated to investing or financing activities	1,052	1,504
Interest paid	-27	-14
Interest payments received	279	142
Income taxes paid	-37	-92
Income taxes received	194	235
	5,412	3,608
2. CASH FLOW FROM INVESTMENT ACTIVITIES		
Cash paid for investments in property, plant and equipment / intangible assets	-2,860	-3,027
Cash receipt for investments in financial assets	0	0
Cash paid from disposal of fixed assets	0	0
Cash paid from purchase price adjustments at subsidiaries	0	0
Acquisition of consolidated companies, net of purchased cash	0	-252
Cash receipts from disposal of securities	0	2,529
Cash paid for investments in securities	0	0
	-2,860	-750
3. CASH FLOW FROM FINANCING ACTIVITIES		
Dividends paid to minority shareholders	0	0
Payments into equity capital via exercise of stock options	0	0
Purchase of own shares	0	0
Payments for taking loans within the context of short-term payment disposal	0	0
Cash receipts from issuing short-term loans	-286	135
	-286	135
4. CASH AND CASH EQUIVALENTS AT END OF FISCAL YEAR		
Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	2,266	2,993
Change in currency translation adjustment	2	33
Consolidation circle-conditional change of financial funds	0	0
Cash and cash equivalents at beginning of fiscal year	9,538	4,141
	11,806	7,167
5. COMPOSITION OF CASH AND CASH EQUIVALENTS		
Cash on hand	11,802	7,413
Bank liabilities due on demand	4	-246
	11,806	7,167

Facts and Figures Development of Group Equity as of 03/31/2010 and 03/31/2009 (IFRS)

DEVELOPMENT OF GROUP EQUITY	SUBSCRIBED CAPITAL	CAPITAL RESERVES	OTHER PROVISIONS	EQUITY DIFFERENCE FROM CURRENCY CONVERSION	RESERVE FOR FINANCIAL INSTRUMENTS	RESERVE FOR PENSIONS	CONSOLIDATED LOSS CARRY FORWARD	CONSOLIDATED DEFICIT / PROFIT	TREASURY STOCK	EQUITY CAP , ATTRIBUTABLE TO STOCKH, OF PARENT COMPANY	MINORITY INTEREST	TOTAL EQUITY	AUTHORIZED CAPITAL
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
CONSOLIDATED EQUITY AS OF 12/31/2008	13,805	39,483	0	59	-999	-72	-9,503	1,488	-26	44,235	259	44,494	6,860
Transfer of 2008 consolidated loss to consolidated loss carry-forward							1,488	-1,488		0		0	
Total income entered directly in equity capital				-79	147	8			-1	74		74	
Profit before tax 03/31/2009								803		803	46	849	
OVERAL RESULT OF THE PERIOD	0	0	0	-79	147	8	0	803	-1	877	46	923	
Stock-based payment		27								27		27	
CONSOLIDATED EQUITY ON 06/30/2008	13,805	39,510	0	-20	-852	-64	-8,015	803	-27	45,140	305	45,445	6,860
CONSOLIDATED EQUITY ON 12/31/2008	13,805	39,523	0	59	-558	-109	-8,016	2,119	-26	46,799	243	47,042	6,860
Profit before tax 2009 entered directly in accumulated deficit							2,119	-2,119		0		0	
Total income entered directly in equity capital				143	51	-18				176		176	
Profit before tax 03/31/2010								1,498		1,498	40	1,538	
OVERAL RESULT OF THE PERIOD	0	0	0	143	51	-18	0	1,498		1,673	40	1,713	
Stock-based payment										0		0	
CONSOLIDATED EQUITY ON 03/31/2010	13,805	39,523	0	202	-507	-127	-5,897	1,498	-26	48,472	283	48,755	6,860

Notes to the consolidated interim financial statements

1. Accounting and Valuation Method

This interim report from the NEXUS Group of 30 June 2010 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

14

The regulations of IAS 34 have been observed in the interim report of 30 June 2010. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2009. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2009.

The report has not been audited.

The Group Financial Statement 2009 and the interim report of 30 June 2009 can be seen on the homepage in the Internet at:

<http://www.nexus-ag.de> .

2. Consolidated Group

In addition to the NEXUS AG as parent company, all operatively active domestic and foreign subsidiaries are included in the Group Financial Statement, for which NEXUS AG has the majority of voting rights directly or indirectly.

Four affiliated companies were included in the balance sheets according to the equity method.

LIST OF SUBSIDIARIES CONSOLIDATED	06/30/2010	06/30/2009
	SHARES OF CAPITAL IN %	
FULL CONSOLIDATION		
NEXUS / CIS GmbH. Singen	100.00	100.00
NEXUS / CSO GmbH. Villingen-Schwenningen	100.00	100.00
NEXUS Digitale Dokumentationssysteme Projektentwicklungsges.mbH. Wien (A)	100.00	100.00
NEXUS / DIS GmbH. Frankfurt am Main	100.00	100.00
NEXUS / HOLL GmbH. Ismaning	100.00	100.00
NEXUS / INOVIT GmbH. Ismaning	91.49	91.49
NEXUS / IT GmbH NORD. Villingen-Schwenningen	100.00	100.00
NEXUS / IT GmbH SÜDOST. Singen	50.20	50.20
NEXUS / IT GmbH SÜDWEST. Villingen-Schwenningen	100.00	100.00
NEXUS Italia S.r.l.. Bologna (I)	80.00	80.00
NEXUS Medizinssoftware und Systeme AG. Kreuzlingen (CH)	99.98	99.98
NEXUS Schweiz GmbH. Schwerzenbach (CH)	100.00	100.00
EQUITY-CONSOLIDATION		
G.I.T.S Gesundheitswesen IT-Service GmbH. Fürstenfeldbruck	49.00	49.00
Medidata GmbH. Berlin	25.00	25.00
Paladium-med GmbH. Berlin	20.00	20.00
NEXUS Arabia Ltd.. Riyadh	50.00	50.00
VEGA Software GmbH. Aachen	30.00	30.00

3. Trade accounts receivable and other Assets

IN KEUR	06/30/2009		12/31/2009		06/06/2010	
	short-termed (< 1 year)	long-termed (> 1 year)	short-termed (< 1 year)	long-termed (> 1 year)	short-termed (< 1 year)	long-termed (> 1 year)
TRADE ACCOUNTS RECEIVABLE	12,422	-	12,021	-	12,590	-
RECEIVABLES FROM AFFILIATED COMPANIES	12	-	0	-	0	-
GROSS AMOUNT DUE TO CUSTOMERS FOR PROJECTS AS AN ASSET	0		567	-	137	
OTHER ASSETS	1,641	1,258	415	1,162	1,864	1,048
from interests of not payable stocks	36	-	0	0	0	-
from accounts receivable in the range of value added tax	29	-	0	0	43	-
from loans to employee and third party	10	1,078	3	936	3	1,078
from loans to parent company	5	180	52	226	11	180
from other	1,561	-	360	0	1,807	-
TAGS REFUND CLAIMS	307	-	315	0	181	-

15

The other assets are not interest-bearing and normally are due between 30 and 360 days. Loans to third parties have interest rates of 3.5% and 5% and are normally safeguarded. Receivables from deliveries and services are not interest-bearing and normally are due between 30 and 90 days.

There were receivables from deliveries and services in the amount of KEUR 1,067 30 June 2010 (30 June 2009: KEUR 968) diminished in value. The development of the value adjustment account is as follows:

ADJUSTMENT ACCOUNT	06/30/09	12/31/09	06/30/10
	KEUR	KEUR	KEUR
Status January, 1st	968	968	1,067
Allowed expenses allocation	40	696	385
Consumption	-399	-170	-323
Dissolution	-49	-427	-15
STATUS - END OF PERIOD	560	1,067	1,114

4. Securities

SECURITIES IN KEUR	06/30/2009		12/31/2009		06/30/2010	
	purchase costs	market value	purchase costs	market value	purchase costs	market value
Corporate bond	1,090	1,008	0	0	0	0
Money market bond	2,014	1,418	2,014	1,724	2,014	1,747
Shares in funds	719	228	719	257	719	308
TOTAL	3,823	2,654	2,733	1,981	2,733	2,055

16

There were no impairments of value to enter in the reporting year or the previous year.

A valuation reserve for financial instruments was established in equity capital, which shows the profits or losses from the sale of available financial assets minus the deferred taxes applicable to them.

5. Current Liabilities

IN KEUR	06/30/2009		12/31/2009		06/30/2010	
	short-termed (< 1 year)	long-termed (> 1 year)	short-termed (< 1 year)	long-termed (> 1 year)	short-termed (< 1 year)	long-termed (> 1 year)
BANK LOANS	246	-	290	-	4	-
RECEIVED ORDER DEPOSITS	557	-	1,483	-	501	-
LIABILITIES FROM DELIVERIES AND SERVICES	2,677	-	3,515	-	2,194	-
LIABILITIES WITH ASSOCIATED COMPANIES	-	-	-	-	-	-
TAX LIABILITIES	606	-	853	-	391	-
OTHER LIABILITIES	2,045	-	2,854	-	3,448	-
for obligations for salary payments	1,423	-	2,060	-	1,907	-
for liabilities of social securities	108	-	130	-	338	-
Others	514	-	664	-	1,203	-

Conditions of the financial liabilities listed above:

- Liabilities to banks serve solely for short-time payments. Interest due here is paid monthly.
- Average down payments on orders are offset after 12 months.
- Liabilities from deliveries and services are not interest-bearing and normally are due with 30 days.

6. Segment reporting

BUSINESS SEGMENTS REPORTING AS OF 30 JUNE	HEALTHCARE SOFTWARE		HEALTHCARE SERVICE		KONSOLIDIE- RUNG		KONZERN	
	2010	2009	2010	2009	2010	2009	2010	2009
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Sales with third parties	18,510	16,667	2,221	2,162			20,731	18,829
-Deliveries	619	756	528	763			1,147	1,519
-Services	4,828	3,495	1,224	1,022			6,052	4,517
-Software updating and hardware maintenance	8,521	8,000	224	248			8,745	8,248
-Licenses	4,542	4,416	245	129			4,787	4,545
Sales between segments	2,854	1,639	250	533	-3,104	-2,172		
Segment sales	21,364	18,306	2,471	2,695	-3,104	-2,172	20,731	18,829
Operating segment result	1,391	402	185	380			1,576	982
Segment assets	44,777	43,266	817	1,010			45,594	44,276

17

Segmenting according Business Divisions

The Group is split into business units according to products and services for the purpose of company management and has the following business segments required to file reports:

Healthcare Software

In the areas NEXUS / CIS, NEXUS / CSO, NEXUS / DIS and NEXUS / HOSPIS (Switzerland), software solutions for the healthcare system are developed and marketed in administrative and medical areas. NEXUS provides a hospital information system (HIS) with its core product NEXUS / HIS for the medical sector. The counterpart product NEXUS / PSYCHIATRY is offered for psychosomatic institutions. We provide all administration applications for the Swiss market with the product line NEXUS / HOSPIS.

Highly specialized solutions are available for radiology, gynecology including obstetrics, pathology and cytology. The leading system for QM assessment of all customary processes (NEXUS / HOLL) has also been assigned to this area. NEXUS also expanded its portfolio for quality management software with the product NEXUS / CURATOR.

Healthcare Service

The Healthcare Service Division covers the services, which are provided by NEXUS / IT companies. These including consulting for hospital IT departments, configuration of network, Intranet and Internet solutions, security concepts and the management of IT services with the context of the service company G.I.T.S. Gesundheitswesen IT-Service GmbH, Fürstenfeldbruck.

The Group is mainly controlled according to business divisions due to the chance and risk structure. Consequently, the division according to business divisions is the primary segmentation level.

Transactions between the segments are mainly debited as procurement or manufacturing costs.

6. Seasonal Influences on the Business Activities

Seasonal effects resulted in the NEXUS Group operations with regards to the receipt of maintenance revenues in the first quarter of the financial year (deferment of the influences on the result of corresponding incoming payments throughout the year) and significantly greater demand and project accounting in the fourth quarter of the financial year.

18

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, August 16, 2010

NEXUS AG
Executive Board

nexus/ag

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888
www.nexus-ag.de, info@nexus-ag.de